Faculty

Institution

Unit

Venue

Michael Nakazawa

The University of Texas MD Anderson Cancer Center

Affiliations

Departments Of Sarcoma Medical Oncology And Paediatrics

The University of Texas MD Anderson Cancer Center

NoneMichael Nakazawa is currently serving as a Departments Of Sarcoma Medical Oncology And Paediatrics faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael Nakazawa

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology sarcoma radiation oncology pathology malignant disease cancer care cancer treatment cancer research leukemia cancer immunotherapy surgical oncology immunology oncogenes molecular cancer cancer genomics cancer biology pharmacology dna repair medicinal research surgical pathology tumor targeting cancer genetics immunotherapy molecular diagnostics histopathology cellular therapy brain tumor research cancer management tumoral pathology tumor innervation melanoma immune checkpoint blockade metastatic melanoma ddr-deficient leiomyosarcomas therapeutic targets gastroenterology cancer discovery cancer cells cancer imaging french studies gynecologic oncology drug targeting novel therapies gastrointestinal oncology tumor heterogeneity tumor suppressors immune checkpoint inhibitors systemic therapy anti-cancer agents skin cancer case series comparative analysis molecular pathology liver cancer endocrine oncology targeted therapy clinical next generation complete loss low immune infiltrate complex genome first-line systemic therapies single-institution cohort clinical characteristics md anderson experience tfcp2 fusion-positive rhabdomyosarcomas rare resistant subclones adult alveolar rhabdomyosarcoma front-line therapies

Notable Scholarly Works

Notable Federal Grants

Collaborators

Pleomorphic Rhabdomyosarcoma, Outcomes of Patients With Advanced Disease Treated With Systemic Agents: Retrospective Study From the Global Pushing Ultra-Rare Sarcomas Towards Hope (Push) Consortium. European Journal of Cancer (2026)

surgical oncologymedicinesarcomapleomorphic rhabdomyosarcomaoncologyradiation oncologycancer caresystemic agentscancer treatmentmalignant diseasepathologyultra-rare sarcomas towards

Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. Frontiers in Immunology (2025)

cancer immunotherapysarcomaoncologymd anderson experiencedermatologyimmunotherapyimmune checkpoint blockadeimmunologypathology

Doxorubicin-Based Chemotherapy vs Gemcitabine/Docetaxel in Uterine Leiomyosarcoma (Ulms).. Journal of Clinical Oncology (2025)

gynecologyuterine leiomyosarcomasarcomagynecologic cancersoncologycancer managementcancer carecancer treatmentgynecologic oncology

Nf1- and Non-Nf1–Associated Malignant Peripheral Nerve Sheath Tumors (Mpnst): The University of Texas MD Anderson (Mdacc) Experience.. Journal of Clinical Oncology (2025)

neuropathologysarcomaoncologyradiation oncologytumoral pathologysurgical pathologybrain tumor researchendocrine oncologygliomastumor innervationmalignant diseasetexas md andersonpathology

Tfcp2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature. Cancers (2025)

sarcomaoncologyradiation oncologycancer researchhistopathologysurgical pathologymalignant diseasetfcp2 fusion-positive rhabdomyosarcomaspathology

Abstract 5661: Identifying and Intervening Rare Resistant Subclones to Braf/Mek Inhibitors in Metastatic Melanoma. Cancer Research (2024)

Han WangMichael NakazawaOmid VeisehLawrence KwongDavid Zhang

cancer immunotherapycancer biologydrug resistanceleukemiapharmacologyrare resistant subclonesmelanomacellular therapyoncologycancer researchmetastatic melanomacancer carecancer treatmentdrug discoveryradiation oncologymolecular cancertumor targetingmedicinal researchdermatologyskin cancer

Clinical Characteristics and Outcomes of Adult Alveolar Rhabdomyosarcoma Patients on First-Line Systemic Therapies: A Single-Institution Cohort. Rare Tumors (2024)

surgical oncologymedicinesarcomaoncologyradiation oncologycancer carecancer treatmentclinical characteristicsfirst-line systemic therapiessingle-institution cohort

Data From Loss of the Dna Repair Gene Rnase H2 Identifies a Unique Subset of Ddr-Deficient Leiomyosarcomas. (2024)

Michael S. NakazawaIan M. SilvermanVictoria RimkunasArtur VelosoDominik GlodzikAdrienne JohnsonToshiro K. OhsumiShreyaskumar R. PatelAnthony P. ConleyChristina L. RolandPamela T. SolimanHannah C. BeirdChia-Chin WuDavis R. IngramRossana LazcanoDawon SongKhalida M. WaniAlexander J. LazarTimothy A. YapWei-Lien WangJ. Andrew Livingston

cancer genomicsgeneticsddr-deficient leiomyosarcomascancer biologyleukemiagenomicsdna repairmolecular biologycancer genetics

Die Zukunft Der Zielgerichteten Therapie Des Leiomyosarkoms. Kompass Onkologie (2024)

french studieslatin literaturecomparative analysisfrench

High-Grade Pleomorphic Sarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (2024)

cancer immunotherapycellular therapysarcomaoncologyradiation oncologyimmune checkpoint inhibitorsimmunotherapyoncogenesimmune checkpoint blockadeimmunologycancer treatmentmalignant diseasepathology

1
2
10 / page

Michael Nakazawa

The University of Texas MD Anderson Cancer Center

Affiliations

Departments Of Sarcoma Medical Oncology And Paediatrics

The University of Texas MD Anderson Cancer Center

NoneMichael Nakazawa is currently serving as a Departments Of Sarcoma Medical Oncology And Paediatrics faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael Nakazawa

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

surgical oncologymedicinesarcomapleomorphic rhabdomyosarcomaoncologyradiation oncologycancer caresystemic agentscancer treatmentmalignant diseasepathologyultra-rare sarcomas towards

Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. Frontiers in Immunology (2025)

cancer immunotherapysarcomaoncologymd anderson experiencedermatologyimmunotherapyimmune checkpoint blockadeimmunologypathology

Doxorubicin-Based Chemotherapy vs Gemcitabine/Docetaxel in Uterine Leiomyosarcoma (Ulms).. Journal of Clinical Oncology (2025)

gynecologyuterine leiomyosarcomasarcomagynecologic cancersoncologycancer managementcancer carecancer treatmentgynecologic oncology

Nf1- and Non-Nf1–Associated Malignant Peripheral Nerve Sheath Tumors (Mpnst): The University of Texas MD Anderson (Mdacc) Experience.. Journal of Clinical Oncology (2025)

neuropathologysarcomaoncologyradiation oncologytumoral pathologysurgical pathologybrain tumor researchendocrine oncologygliomastumor innervationmalignant diseasetexas md andersonpathology

Tfcp2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature. Cancers (2025)

sarcomaoncologyradiation oncologycancer researchhistopathologysurgical pathologymalignant diseasetfcp2 fusion-positive rhabdomyosarcomaspathology

Abstract 5661: Identifying and Intervening Rare Resistant Subclones to Braf/Mek Inhibitors in Metastatic Melanoma. Cancer Research (2024)

Han WangMichael NakazawaOmid VeisehLawrence KwongDavid Zhang

Clinical Characteristics and Outcomes of Adult Alveolar Rhabdomyosarcoma Patients on First-Line Systemic Therapies: A Single-Institution Cohort. Rare Tumors (2024)

surgical oncologymedicinesarcomaoncologyradiation oncologycancer carecancer treatmentclinical characteristicsfirst-line systemic therapiessingle-institution cohort

Data From Loss of the Dna Repair Gene Rnase H2 Identifies a Unique Subset of Ddr-Deficient Leiomyosarcomas. (2024)

cancer genomicsgeneticsddr-deficient leiomyosarcomascancer biologyleukemiagenomicsdna repairmolecular biologycancer genetics

Die Zukunft Der Zielgerichteten Therapie Des Leiomyosarkoms. Kompass Onkologie (2024)

french studieslatin literaturecomparative analysisfrench

High-Grade Pleomorphic Sarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (2024)

cancer immunotherapycellular therapysarcomaoncologyradiation oncologyimmune checkpoint inhibitorsimmunotherapyoncogenesimmune checkpoint blockadeimmunologycancer treatmentmalignant diseasepathology

1
2
10 / page